ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1626

Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus

Mario Cesar Ocampo Torres 1, Elizabeth Olivares-Martinez 2 and Juanita Romero-Diaz3, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cardiovascular disease, Lupus, osteopontin and risk assessment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background/purpose Premature atherosclerosis has been recognized as a major cause of morbidity and mortality in SLE patients. We aimed to determine 1) the incidence and progression of Coronary-Artery calcification (CAC) and 2) if OPN serum levels are associated with progression of CAC in SLE patients

Methods: Design: Inception Cohort. Since enrollment into the cohort, all patients had a standardized medical history, physical examination, and laboratory tests, including lipid profile, apoB, homocystein, high-sensitivity C-reactive protein (hs-CRP), serum complement (C3 and C4), and autoantibodies. Every 3-6 months, patients have been seen at the lupus clinic for medical care, and assessments of disease activity using the SLE disease activity scores, and medications usage. Every year, information has been updated, including irreversible damage accrual, any co-morbidities, traditional cardiovascular risk-factors, and a blood sample has been drawn. In 2008, 104 lupus patients from the cohort (93% females) were screened for coronary-artery calcifications using Multidetector Computed Tomography, after first 5 years of follow-up. In 2018 a follow-up screening for CAC was carried-up. Progression of CAC was considered as positive if i) patients without CAC in 2008 were found with CAC+ in the second screening or ii) patients with CAC positive in 2008 were found with any increase of their Calcium Score. OPN plasma levels were measured by ELISA. Correlates for calcifications were analyzed. Cumulative incidence of CAC was calculated and risk factors for CAC progression were identified by multivariate analysis.

Results: At-enrollment, lupus patients were 27.2+9.1 years of age and disease duration 5.4+3.8 months.. On 2008 during the first screening, CAC were detected in 7. 2% patients, since age 23 years, and from three years of disease duration. At follow-up screening, progression of CAC was identified in 16. 3% (IC95% 10. 4-24. 6). Cumulative incidence of CAC was observed in 9%. Mean value of OPN level at baseline was 102.7 ng/mL (95% CI = 89.3-116.1 ng/mL). Earlier Risk factors associated with CAC were disease activity (p=0. 03) and disease duration (p=0. 03) while risk factors for progression of CAC were postmenopausal status (p=0. 01), apoB levels (p=0. 01) and OPN levels (p=0.009). There was a positive correlation for progression of CAC and adjusted mean SLEDAI at first 5 years of follow-up and baseline OPN levels (p=0.006).

Conclusion: Our findings suggest that in patients with SLE, early CAC is associated with disease severity while in the progression of CAC, traditional risk factors atherosclerosis and OPN level were adding


Disclosure: M. Ocampo Torres, None; E. Olivares-Martinez, None; J. Romero-Diaz, None.

To cite this abstract in AMA style:

Ocampo Torres M, Olivares-Martinez E, Romero-Diaz J. Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/baseline-serum-osteopontin-opn-level-is-associated-with-early-coronary-artery-calcification-and-its-progression-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-serum-osteopontin-opn-level-is-associated-with-early-coronary-artery-calcification-and-its-progression-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology